Peter B Berger

Summary

Affiliation: Geisinger Medical Center
Country: USA

Publications

  1. doi request reprint Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?
    Peter B Berger
    Geisinger Clinic, Danville, Pennsylvania, USA
    J Interv Cardiol 26:123-30. 2013
  2. doi request reprint Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
    Peter B Berger
    Director, Center for Clinical Studies, 100 N Academy Ave, MC 44 00, Danville, PA 17822, USA
    Circulation 121:2575-83. 2010
  3. doi request reprint Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
    Peter B Berger
    Geisinger Clinic, Danville, Pennsylvania 17822 4400, USA
    JACC Cardiovasc Interv 3:920-7. 2010
  4. doi request reprint Frequency of coronary angiography and revascularization among men and women with myocardial infarction and their relationship to mortality at one year: an analysis of the Geisinger myocardial infarction cohort
    Kimberly A Skelding
    Geisinger Medical Center, Danville, Pennsylvania, USA
    J Interv Cardiol 26:14-21. 2013
  5. doi request reprint Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    Christopher W Good
    Geisinger Clinic, Danville, PA, USA
    Circ Cardiovasc Interv 5:77-81. 2012
  6. doi request reprint Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarction
    C Randall Hubbard
    Department of Cardiology, Geisinger Medical Center, Danville, PA, USA
    Am J Cardiol 102:1469-72. 2008
  7. doi request reprint Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel
    Juzar O Lokhandwala
    Department of Cardiology, Geisinger Medical Center, Danville, PA 17822 3003, USA
    Circ Cardiovasc Interv 2:348-51. 2009
  8. doi request reprint Readmission in the 30 days after percutaneous coronary intervention
    Gregory W Yost
    Department of Cardiology, Geisinger Medical Center, Danville, PA 17822, USA
    JACC Cardiovasc Interv 6:237-44. 2013
  9. doi request reprint Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting
    James C Blankenship
    Department of Cardiology, Geisinger Medical Center, Danville, Pennsylvania 17822, USA
    J Am Coll Cardiol 57:272-9. 2011
  10. doi request reprint Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial
    James C Blankenship
    Department of Cardiology, Geisinger Medical Center, Danville, Pennsylvania, USA
    Am J Cardiol 106:1527-33. 2010

Detail Information

Publications14

  1. doi request reprint Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?
    Peter B Berger
    Geisinger Clinic, Danville, Pennsylvania, USA
    J Interv Cardiol 26:123-30. 2013
    ..To investigate whether tirofiban would have been non-inferior to abciximab had the trial completed enrollment and place the termination of this trial in a broader research ethics context...
  2. doi request reprint Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
    Peter B Berger
    Director, Center for Clinical Studies, 100 N Academy Ave, MC 44 00, Danville, PA 17822, USA
    Circulation 121:2575-83. 2010
    ..We sought to determine the frequency and time course of bleeding with DAPT in patients with established vascular disease or risk factors only; identify correlates of bleeding; and determine whether bleeding is associated with mortality...
  3. doi request reprint Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
    Peter B Berger
    Geisinger Clinic, Danville, Pennsylvania 17822 4400, USA
    JACC Cardiovasc Interv 3:920-7. 2010
    ..This study sought to determine the frequency of noncardiac surgery and adverse post-operative events among patients who recently received a drug-eluting stent (DES) following noncardiac surgery...
  4. doi request reprint Frequency of coronary angiography and revascularization among men and women with myocardial infarction and their relationship to mortality at one year: an analysis of the Geisinger myocardial infarction cohort
    Kimberly A Skelding
    Geisinger Medical Center, Danville, Pennsylvania, USA
    J Interv Cardiol 26:14-21. 2013
    ..To determine sex bias in the selection of strategies to evaluate patients with acute myocardial infarction (AMI), and determine if the choice of strategy influences survival...
  5. doi request reprint Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    Christopher W Good
    Geisinger Clinic, Danville, PA, USA
    Circ Cardiovasc Interv 5:77-81. 2012
    ..Several studies have reported that CCBs reduce the ability of clopidogrel to inhibit platelet aggregability; one suggested that CCBs reduce the efficacy of clopidogrel...
  6. doi request reprint Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarction
    C Randall Hubbard
    Department of Cardiology, Geisinger Medical Center, Danville, PA, USA
    Am J Cardiol 102:1469-72. 2008
    ..In conclusion, some patients with previous contrast reaction may undergo emergency catheterization without adverse consequences, although the safety of this approach has not been proved...
  7. doi request reprint Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel
    Juzar O Lokhandwala
    Department of Cardiology, Geisinger Medical Center, Danville, PA 17822 3003, USA
    Circ Cardiovasc Interv 2:348-51. 2009
    ..It is also unknown whether a reaction to the second thienopyridine is likely to be life threatening...
  8. doi request reprint Readmission in the 30 days after percutaneous coronary intervention
    Gregory W Yost
    Department of Cardiology, Geisinger Medical Center, Danville, PA 17822, USA
    JACC Cardiovasc Interv 6:237-44. 2013
    ..This study sought to identify the frequency and etiology of readmission within 30 days of percutaneous coronary intervention (PCI) in a large integrated healthcare system...
  9. doi request reprint Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting
    James C Blankenship
    Department of Cardiology, Geisinger Medical Center, Danville, Pennsylvania 17822, USA
    J Am Coll Cardiol 57:272-9. 2011
    ..The purpose of this study was to demonstrate the feasibility of routine transfer of ST-segment elevation myocardial infarction (STEMI) patients to achieve percutaneous coronary intervention (PCI) in less than 90 min from presentation...
  10. doi request reprint Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial
    James C Blankenship
    Department of Cardiology, Geisinger Medical Center, Danville, Pennsylvania, USA
    Am J Cardiol 106:1527-33. 2010
    ..Systems of care that encourage ambulance diagnosis and direct delivery of patients with STEMI to a PCI hospital might shorten the overall door-to-balloon times and improve the clinical outcomes...
  11. doi request reprint ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time
    James C Blankenship
    Department of Cardiology, Geisinger Medical Center, Danville, PA 17822, USA
    Am Heart J 158:400-7. 2009
    ..We sought to determine whether STEMI patients treated with PCI could be enrolled in clinical trials without prolonging door-to-balloon times...
  12. doi request reprint The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy
    Nicholas J Toepfer
    Department of Urology, Cardiovascular Center for Clinical Research, Geisinger Clinic, Danville, PA Electronic address
    Urology 82:773-9. 2013
    ..To determine if there is any difference in the clinical outcome for patients receiving aspirin, clopidogrel, and warfarin undergoing ureteroscopy and laser lithotripsy for urolithiasis compared with patients on no antithrombotic medication...
  13. doi request reprint P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
    Christopher W Good
    Geisinger Center for Clinical Studies, MC 40 04, Danville, PA 17822, USA
    Curr Cardiol Rep 13:320-6. 2011
    ..This review focuses on P2Y12 antagonists as one component of our armamentarium of antiplatelet therapies, specifically on data addressing in whom, when, which agent, and in what dose such agents should be administered...
  14. ncbi request reprint Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era
    Christopher W Good
    Department of Cardiology, Geisinger Medical Center, Danville, PA 17822, USA
    J Invasive Cardiol 21:194-200. 2009
    ..The frequency of ad hoc percutaneous coronary intervention (PCI) varies among institutions and regions of the country. It is unclear what factors limit use of the ad hoc strategy...